Abstract
Aim. The Department of Biochemistry and Physiology of Animals, named after Academician Guly NUBIP of Ukraine, developed magnesium and phosphorus combined medication based on casein. Our aim was to test its bioavailability based on the ability to be hydrolyzed by a mixture of pancreatic digestive enzymes trypsin and chymotrypsin, also check the absence of cytotoxic effects on cell cultures. Methods. To assess bioavailability, we used hydrolysis of the medication with a mixture of trypsin and chymotrypsin, followed by detection of hydrolysis products by polyacrylamide gel electrophoresis. A standard MTT-test performed on both MT-4 and Namalva cell lines was used to assess cytotoxic effects. Results. Based on electrophoresis data, it was found that despite chemical modifications of the natural casein, the medication based on it is characterized by a high ability to hydrolyze by digestive enzymes under the same conditions as casein. Also, an MTT-test demonstrates that the medication has no cytotoxic properties against cell lines MT-4 and Namalva. Conclusions. Since the negative effects of the drug associated with its digestibility and toxicity have not been observed, it is recommended to continue the study of its effects on living organisms.
Publisher
National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference31 articles.
1. 1. Pasternak K., Kocot J., Horecka A. Biochemistry of Magnesium. J. Elem. 2010, 15 (3), 601-616. https://doi.org/10.5601/jelem.2010.15.3.601-616
2. 2. Fawcett W. J., Haxby E. J., Male D. A. Magnesium: Physiology and Pharmacology. Brit. J. Anesthesia. 1999, 83 (2), 302-320. https://doi.org/10.1093/bja/83.2.302
3. 3. Elin R. J. Magnesium Metabolism in Health and Disease. Disease-a-Month. 1988, 34 (4), 161-218. https://doi.org/10.1016/0011-5029(88)90013-2
4. 4. Swaminathan R. Magnesium Metabolism and its Disorders. Clin. Biochem. Rev. 2003, 24 (2), 47-66. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1855626/
5. 5. Butafosfan: Committee for Veterinary Medicinal Products, Summary Report 1. The European Agency for the Evaluation of Medicinal Products, Veterinary Medicines, and Information Technology Unit. 1999, 630 (99), 1-3. https://www.ema.europa.eu/en/documents/mrl-report/butafosfan-summary-report-1-committee-veterinary-medicinal-products_en.pdf